Approach to the Patient With Parathyroid Carcinoma
The Journal of Clinical Endocrinology & Metabolism · 21.12.2023 · 109 (1) · 256-268
DOI: 10.1210/clinem/dgad455 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 02.08.2023. Verfasst von Filomena Cetani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Endocrinology, University Hospital of Pisa, 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Parathyroid Neoplasms, Hypercalcemia. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 135 Literaturangaben.
Abstract (Originalsprache)
Parathyroid carcinoma (PC) is usually associated with severe symptomatic primary hyperparathyroidism (PHPT) and accounts for less than 1% of all cases of PHPT and approximately 0.005% of all cancers. PC most commonly occurs as a sporadic disease and somatic CDC73 mutations can be detected in up to 80% of cases. Approximately 30% of patients harbor a germline mutation of the CDC73 gene. Preoperative diagnosis of PC is difficult because no disease-specific markers are available, and PC should be suspected in patients with severe hypercalcemia and end-organ complications. The diagnosis is based on the evidence of invasive tumor growth at histology and/or metastases. En bloc resection of the tumor, together with the ipsilateral thyroid lobe and adjacent structures, should be performed by an experienced surgeon when PC is suspected. This surgical approach reduces the risk of recurrence and metastasis and offers the highest chance of cure. Nonetheless, PC has a recurrence rate of 40% to 60% and, if feasible, multiple surgical procedures should be performed. When surgery is no longer an option, medical treatment is aimed to reduce hypercalcemia and target organ complications. Targeted agents have been effectively used in a few cases. We describe herein a patient with severe PHPT due to PC and provide a systematic diagnostic and treatment approach. A thorough review of the medical history, a typical clinical and biochemical phenotype and, in some cases, the revision of the histological examination provide the clues for the diagnosis of PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Endocrinology, University Hospital of Pisa, 56124 Pisa, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy.
- Department of Surgical, Medical, Molecular Pathology and Clinical Area, University of Pisa, 56126 Pisa, Italy.
ORCID-Profile: Filomena Cetani
Zitieren
APA
Cetani, F., Pardi, E., Torregrossa, L., Borsari, S., Pierotti, L., Dinoi, E., & Marcocci, C. (2023). Approach to the Patient With Parathyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism, 109(1), 256-268. https://doi.org/10.1210/clinem/dgad455
Vancouver
Cetani F, Pardi E, Torregrossa L, Borsari S, Pierotti L, Dinoi E, et al. Approach to the Patient With Parathyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2023;109(1):256-268. doi:10.1210/clinem/dgad455
BibTeX
@article{Cetani2023,
author = {Cetani, Filomena and Pardi, Elena and Torregrossa, Liborio and Borsari, Simona and Pierotti, Laura and Dinoi, Elisa and Marcocci, Claudio},
title = {Approach to the Patient With Parathyroid Carcinoma},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {109},
number = {1},
pages = {256--268},
doi = {10.1210/clinem/dgad455}
}
EUVIMED